^
BIOMARKER:

EML4-ALK fusion

i
Other names: EML4, EMAP Like 4, Restrictedly Overexpressed Proliferation-Associated Protein, Echinoderm Microtubule-Associated Protein-Like 4, Echinoderm Microtubule Associated Protein Like 4, Ropp 120, C2orf2, EMAP-4, EMAPL4, ROPP120, ELP120, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
EML4-ALK fusion
NSCLC
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
EML4-ALK fusion
NSCLC
crizotinib
Resistant: C3 – Early Trials
EML4-ALK fusion
Ovarian Cancer
alectinib
Sensitive: C4 – Case Studies
EML4-ALK fusion
Breast Cancer
crizotinib
Sensitive: C4 – Case Studies
EML4-ALK fusion
LUAD
GC
Resistant: C4 – Case Studies
EML4-ALK fusion
LUAD
crizotinib
Sensitive: C4 – Case Studies
EML4-ALK fusion
Lung Non-Small Cell Squamous Cancer
brigatinib
Sensitive: C4 – Case Studies
EML4-ALK fusion
Lung Non-Small Cell Squamous Cancer
alectinib
Sensitive: C4 – Case Studies
EML4-ALK fusion
NSCLC
MTI-31
Sensitive: D – Preclinical
EML4-ALK fusion
NSCLC
ADX-1612
Sensitive: D – Preclinical
EML4-ALK fusion
NSCLC
ceritinib
Sensitive: D – Preclinical
EML4-ALK fusion
NSCLC
ceritinib + U0126
Sensitive: D – Preclinical
EML4-ALK fusion
NSCLC
lorlatinib
Resistant: D – Preclinical
EML4-ALK fusion
Melanoma
crizotinib
Sensitive: D – Preclinical
EML4-ALK fusion
Melanoma
ceritinib
Sensitive: D – Preclinical
EML4-ALK fusion
NSCLC
gilteritinib
Sensitive: D – Preclinical